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OBJECTIVE: Pulmonary embolism is an underdiagnosed major cause of death for hospitalized patients. The
objective of this study was to identify the conditions associated with fatal pulmonary embolism in this
population.
METHODS: A total of 13,074 autopsy records were evaluated in a case-control study. Patients were matched by
age, sex, and year of death, and factors potentially associated with fatal pulmonary embolism were analyzed
using univariate and multivariate conditional logistic regression.
RESULTS: Pulmonary embolism was considered fatal in 328 (2.5%) patients. In the multivariate analysis,
conditions that were more common in patients who died of pulmonary embolism were atherosclerosis,
congestive heart failure, and neurological surgery. Some conditions were negatively associated with fatal
pulmonary embolism, including hemorrhagic stroke, aortic aneurism, cirrhosis, acquired immune deficiency
syndrome, and pneumonia. In the control group, patients with hemorrhagic stroke and aortic aneurism had
short hospital stays (8.5 and 8.8 days, respectively), and the hemorrhage itself was the main cause of death in
most of them (90.6% and 68.4%, respectively), which may have prevented the development of pulmonary
embolism. Cirrhotic patients in the control group also had short hospital stays (7 days), and 50% died from
bleeding complications.
CONCLUSIONS: In this large autopsy study, atherosclerosis, congestive heart failure, and neurological surgery
were diagnoses associated with fatal pulmonary embolism.
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& INTRODUCTION
Venous thromboembolism (VTE) is a major cause of
morbidity and mortality (10), and pulmonary embolism
(PE) is responsible for up to 10% of hospitalized patient
deaths (2). The estimates of PE prevalence in patients at risk
for VTE have been derived from the results of randomized
clinical trials, and prospective population-based analyses
have provided additional insight into the risk of the
population as a whole (1–4). However, the literature
contains few studies that describe the incidence or the
clinical characteristics of hospitalized patients who suffer
from fatal VTE events.
Risk stratification and preventive strategies for both
surgical and medical patients are presented in the
American College of Chest Physicians Guidelines for VTE
prophylaxis (3). Risk in surgical patients is based on age, the
type of surgery, and the presence of other VTE risk factors.
In medical patients, prophylaxis is recommended in cases of
congestive heart failure (CHF) or severe respiratory disease
and for bedridden patients with active cancer, previous
VTE, sepsis, acute neurologic disease, or inflammatory
bowel disease. Other guidelines recommend thrombopro-
phylaxis for medical patients aged over 40 years who
demonstrate reduced mobility associated with additional
risk factors (4).
While the indications for thromboprophylaxis are well
established, the diagnosis of PE remains a significant
clinical challenge (5–8). Autopsy remains the gold standard
for diagnosing fatal PE, but the number of autopsies
performed has decreased substantially in many countries
(9–11). In addition, recent studies have recognized PE as
one of the most frequently missed diagnoses in living
patients (12–15).
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In this retrospective matched case-control study, we
analyzed the autopsy records of 13,074 patients with the
primary objective of identifying conditions associated with
fatal PE in hospitalized clinical and surgical patients. Our
results may aid in identifying patients who could benefit
from VTE prophylaxis and whose risks should be empha-
sized. The clinical suspicion of PE prior to death was also
investigated.
& MATERIALS AND METHODS
Study population
This study was performed in a 1,100-bed university
hospital at the Faculdade de Medicina da Universidade de
Sa˜o Paulo in Brazil, which admits adult medical and general
surgery patients. Autopsies are routinely performed if
requested by physicians and when considered necessary.
This study was approved by the local ethical committee
(protocol number 901/03).
Study design
All autopsy reports from 1995 to 2004 were screened, and
autopsies in which PE was a finding (as determined by
pathologists) were selected for review. We chose the years
1995 to 2004 because autopsies were much more common
during this period compared to the following years (70% of
total deaths), thereby avoiding selection bias. The autopsy
protocol included a systematic search for pulmonary
thrombi in all pulmonary lobes and a microscopic analysis
of all suspect areas of the lungs. For each confirmed PE case,
two additional patients matched by sex, age (¡5 years), and
year of death were selected as controls. Patients without PE
but with deep vein thrombosis (DVT), as noted on the
autopsy reports, were not eligible for use as controls.
Pediatric and orthopedic patients were typically admitted to
other institutes within the hospital complex and were not
included in this study. All autopsy reports and discharge
summaries were independently reviewed by two physicians
from the research group (EFP and AL) to classify PE as the
primary cause or a contributing factor of death (‘‘fatal’’ and
‘‘non-fatal’’ PE), define the main reason for hospital
admission, to identify whether a PE diagnosis was
suspected before the autopsy. PE was considered fatal
when the pathologists classified it as the only or main cause
of death. The consensus reached between the two classify-
ing physicians was 97%. When the two physicians dis-
agreed, the case was reevaluated by both physicians
together to reach a consensus.
All medical records were screened to determine whether
VTE prophylaxis had been prescribed during hospitaliza-
tion. Only unfractionated heparin (UFH) and enoxaparin
were used for prophylaxis. UFH administered every 8 to 12
hours at a dose of 5,000 IU and enoxaparin administered
once daily at a dose of 40 mg (or 20 mg if the creatinine
clearance was below 30 mL/min/1.73 m2) were considered
the proper treatment. For the prophylaxis to be considered
adequate, the patients needed to have received the correct
dose and could not have been subjected to 72 or more
consecutive hours without prophylaxis during any period of
hospitalization.
The entire patient group was considered for the analysis
of PE incidence and the clinical accuracy of PE diagnosis
before death. Only fatal cases and the appropriate controls
were included in the analysis of conditions associated with
PE.
Statistical analysis
A database was created using Microsoft Access Version
2003. Student’s t-test, Fisher’s exact test, and the chi-
squared test were employed to compare characteristics
between the cases and controls. Univariate and multi-
variate conditional logistic regressions were employed to
estimate the association with fatal PE (OR and 95% CI).
These regressions were performed by matching for sex,
age, and year of death, and two controls were evaluated
per case. The multivariate regression model included every
variable that presented a p-value ,0.20 in the univariate
regression. Variables with p-values $0.05 were excluded
sequentially according to decreasing p-values. The final
multivariate model contained only variables with p-values
,0.05. The analyses were performed using the Stata 10.1TM
software.
& RESULTS
Autopsies were performed for 13,074 (71.2%) of the 18,359
deaths. Autopsies from 2002 were excluded because the
hospital’s computer system changed that year, and the new
system was unable to transfer data from the old system.
Table 1 shows how the autopsy rate decreased over the
course of the study period, and a significant difference was
found after 1999. The average percentage of deaths for
which autopsies were performed between 1995 and 1999
was 87%, and it decreased to 53.9% between 2000 and 2004
(p= 0.005).
PE was detected in 502 autopsies (3.8%) and was
considered the main cause of death (fatal PE) in 328 of
these (2.5%) cases. There were no significant differences in
the percentages of autopsies with PE or the percentage of PE
cases classified as fatal or non-fatal over the course of the
study period (Table 1).
The sensitivity of the clinical PE diagnosis was only 48.2%
for the entire group, although it was higher in cases of fatal
PE compared to non-fatal PE (61.9% vs. 22.4%, respectively,
p,0.001). The specificity of the clinical diagnosis of PE was
greater than 98% for all of the subgroups.
For the analysis of conditions associated with PE, 984
patients (328 fatal PE cases and 656 non-PE controls) were
selected. The baseline characteristics are shown in Table 2.
There were no significant differences in gender or age
between the groups, which indicated successful matching.
Arterial insufficiency, atherosclerosis, cancer, CHF, and
chronic obstructive pulmonary disease (COPD) were more
common in the fatal PE group, whereas acquired immuno-
deficiency syndrome (AIDS), aortic aneurism, cirrhosis,
infections, pneumonia, and hemorrhagic stroke were more
common in the control group.
Age and length of stay were analyzed according to the
main disease groups to test the hypothesis that older
patients and those with longer hospital stays would have
greater risks for VTE (Table 3). The only significant
difference was related to the mean hospital stay of patients
with chronic renal failure, which was longer for those in the
fatal PE group (18.7 days vs. 6.2 days in the non-PE group;
p= 0.020).
Table 4 shows the results of the conditional univariate
logistic regression analysis performed to identify conditions
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related to fatal PE autopsy findings and adjusted for sex, age
and admission time. Atherosclerosis (OR= 4.65, 95% CI,
1.23–17.52, p= 0.020), cancer (OR=1.72, 95% CI, 1.28–2.32,
p,0.001), CHF (OR=2.14, 95% CI, 1.30–3.50, p= 0.003), and
COPD (OR=2.75, 95% CI, 1.24–6.10, p= 0.010) were asso-
ciated with fatal PE. Of the types of cancers documented,
brain cancer (OR= 2.91, 95% CI, 1.25–6.74, p=0.010) and
cancer of undetermined origin (OR=3.94, 95% CI, 1.17–
13.28, p= 0.030) were most significantly associated with fatal
PE. Fatal PE was negatively associated with AIDS
(OR=0.30, 95% CI, 0.12–0.77, p= 0.010), aortic aneurism
(OR=0.11, 95% CI, 0.14–0.88, p=0.040), cirrhosis (OR= 0.10,
95% CI, 0.03–0.33, p,0.001), hemorrhagic stroke (OR=0.19,
95% CI, 0.08–0.47, p,0.001), infection (OR=0.60, 95% CI,
0.38–0.97, p= 0.040), and pneumonia (OR=0.39, 95% CI,
0.18–0.85, p= 0.020). In the entire group (n= 1,506), VTE
prophylaxis was considered adequate in only 20.4% of
cases. Lack of prophylaxis was not shown to be associated
with fatal PE in the univariate analysis (Table 4).
The conditional multivariate logistic regression indicated
that fatal PE was associated with atherosclerosis (OR= 4.03,
95% CI, 1.06–15.01, p= 0.040), CHF (OR=1.77, 95% CI, 1.04–
2.97, p= 0.030), and neurological surgery (OR=3.96, 95% CI,
1.48–10.65, p= 0.006). A negative association with fatal PE
was found in patients with AIDS (OR=0.22, 95% CI, 0.08–
0.60, p=0.003), aortic aneurism (OR=0.12, 95% CI, 0.01–
0.90, p= 0.040), cirrhosis (OR= 0.08, 95% CI, 0.03–0.27,
p,0.001), pneumonia (OR=0.35, 95% CI, 0.15–0.79,
p= 0.010), and hemorrhagic stroke (OR=0.09, 95% CI,
0.03–0.25, p,0.001) (Table 5).
& DISCUSSION
VTE prevention in hospitalized patients has improved in
recent years and now includes recommendations for
improving the diagnosis of VTE and new algorithms for
VTE prophylaxis (3,4,16). However, the percentage of
patients whose deaths are the result of PE has not
decreased, and this fact may be related to many factors,
such as the increase in patient age or the large number of
VTE risk factors (3,17). In addition, most doctors do not
follow the appropriate thromboprophylaxis protocols
(18,19). Thus, VTE remains a major cause of death for
hospitalized patients, and a substantial number of VTEs
discovered at autopsy are not diagnosed during hospitaliza-
tion (14,20–23).
Autopsies remain invaluable for determining the effects
of prophylaxis and diagnosing and treating VTE (9);
unfortunately, the number of autopsies performed has
decreased substantially in many countries (10,24).
Although we observed a statistically significant decrease
in the number of autopsies over the study period, the
autopsy rate at our hospital was greater (71.2% of deaths)
than that reported in other studies. Data from the United
States National Center for Health Statistics over a similar
time period showed that the autopsy rate was low in 1993
(9.7% of all deaths in the US) and further decreased to only
7.1% in 2003 (24).
In a classic study by Lindblad, a systematic search for
VTE identified PE in 26.4% of all autopsies (9.4% were
considered fatal PE) (9). The percentage of PE patients in
our patient sample (3.8% for all PE and 2.5% for fatal PE)
was much lower. Differences in the percentages of autopsies
found with PE in the different studies may be caused by
Table 1 - Number and percentage of autopsies performed
and PEs found during the study.
Year
Deaths
n
Autopsies
n (%)
PE
n (%)
Fatal
PE n (%)
Non-fatal
PE n (%)
1995 2189 1990 (90.9) 96 (4.8) 62 (3.1) 34 (1.7)
1996 2114 1767 (83.6) 70 (4.0) 38 (2.2) 32 (1.8)
1997 1905 1525 (80.1) 72 (4.7) 40 (2.6) 32 (2.1)
1998 1741 1502 (86.3) 38 (2.5) 33 (2.2) 5 (0.3)
1999 1654 1571 (95.0) 68 (4.3) 43 (2.7) 25 (1.6)
2000 1964 1345 (68.5) 42 (3.1) 28 (2.1) 14 (1.0)
2001 2248 1273 (56.6) 33 (2.6) 23 (1.8) 10 (0.8)
2003 2216 1063 (48.0) 57 (5.4) 40 (3.8) 17 (1.6)
2004 2328 1038 (44.6) 26 (2.5) 21 (2.0) 5 (0.5)
Total 18359 13074 (71.2) 502 (3.8) 328 (2.5) 174 (1.3)
PE: pulmonary embolism.
Table 2 - Baseline characteristics in fatal PE and non-PE
groups.
Characteristic Fatal PE Non-PE p-value
n=328 n=656
Age in years, mean (SD) 62.2 (16.4) 61.5 (16.5) 0.26
Male, n (%) 163 (49.7) 326 (49.7) 1.00
Length of stay in days, mean (SD) 10.8 (15.1) 11.7 (16.0) 0.200
AIDS, n (%) 7 (2.1) 38 (5.8) 0.009
AMI, n (%) 15 (4.6) 31 (4.7) 1.00
Aortic aneurism, n (%) 1 (0.3) 19 (2.9) 0.006
Arterial insufficiency, n (%) 17 (5.2) 15 (2.3) 0.020
Atherosclerosis, n (%) 7 (2.1) 4 (0.6) 0.049
Cancer, n (%) 135 (41.2) 196 (29.9) 0.001
Biliary tract, n (%) 6 (4.4) 11 (5.6) 0.80
Bladder, n (%) 2 (1.5) 3 (1.5) 1.00
Brain, n (%) 15 (11.1) 10 (5.1) 0.060
Breast, n (%) 9 (6.7) 8 (4.1) 0.32
Colorectal, n (%) 12 (8.9) 16 (8.2) 0.84
Esophagus, n (%) 4 (3.0) 9 (4.6) 0.57
Head and neck, n (%) 4 (3.0) 13 (6.6) 0.200
Kidney, n (%) 2 (1.5) 3 (1.5) 1.00
Leukemia, n (%) 5 (3.7) 15 (7.7) 0.160
Liver, n (%) 3 (2.2) 10 (5.1) 0.26
Lung, n (%) 12 (8.9) 26 (13.3) 0.29
Lymphoma, n (%) 10 (7.4) 20 (10.2) 0.44
Melanoma, n (%) 2 (1.5) 2 (1.0) 1.00
Myeloma, n (%) 3 (2.2) 2 (1.0) 1.00
Ovarian, n (%) 3 (2.2) 4 (2.0) 1.00
Pancreas, n (%) 9 (6.7) 9 (4.6) 1.00
Uterus, n (%) 10 (7.4) 9 (4.6) 0.40
Chronic renal failure, n (%) 6 (1.8) 10 (1.5) 0.80
CHF, n (%) 37 (11.3) 39 (5.9) 0.005
Cirrhosis, n (%) 3 (0.9) 58 (8.8) ,0.001
COPD, n (%) 16 (4.9) 13 (2.0) 0.020
Infections, n (%) 26 (7.9) 84 (12.8) 0.020
Pneumonia 8 (2.4) 39 (5.9) 0.020
Tuberculosis 6 (1.8) 11 (1.7) 1.00
Urinary 5 (1.5) 3 (0.5) 0.130
Endocarditis 3 (0.9) 8 (1.2) 0.76
Peritonitis 1 (0.3) 8 (1.2) 0.29
Others 4 (1.2) 15 (2.3) 0.33
Mesenteric ischemia, n (%) 3 (0.9) 12 (1.8) 0.41
Rheumatologic, n (%) 6 (1.8) 13 (2.0) 1.00
Stroke (hemorrhagic), n (%) 6 (1.8) 53 (8.1) ,0.001
Stroke (ischemic), n (%) 14 (4.3) 25 (3.8) 0.73
Others, n (%) 29 (8.8) 46 (7.0) 0.31
PE: pulmonary embolism; AIDS: acquired immunodeficiency syndrome;
AMI: acute myocardial infarction; CHF: congestive heart failure and COPD:
chronic obstructive pulmonary disease.
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different autopsy protocols, different hospital populations
and the percentage of autopsies performed. We avoided
selection bias by studying a period in which the percentage
of autopsies was particularly high in our hospital, approxi-
mately 70% of the total number of deaths. The small
difference between the number of total PE and fatal PE cases
found in our series may be due to the autopsy protocol used
to search for visible thrombi and perform microscopic
analysis only of the areas with macroscopic findings.
Because the main objective of this study was to identify
conditions associated with fatal PE, this factor was not
considered a major limitation.
Clinical suspicion of PE has a high specificity, but the
reported sensitivity was approximately 30% (20–23).
Sensitivity can also vary from less than 10% to more than
65%, depending on the related conditions. Diagnosis is
typically more difficult in older patients and for those with
respiratory diseases, specifically COPD and pneumonia
(21). The severity of the PE episode may be another possible
explanation for this variation, and this possibility was
demonstrated in the present study, in which the sensitivity
of antemortem diagnoses was much higher in patients with
fatal PE (61.9%) compared to patients with non-fatal PE
(22.4%).
Cancer, CHF, and COPD have long been considered
important risk factors for VTE (3,4,25–27). In the present
study, the association of these factors with fatal PE was
noted in the univariate analysis, but only the association
with CHF was confirmed in the multivariate analysis. The
association between brain cancer and fatal PE was also lost
in the multivariate analysis; however, brain cancer is
considered one of the cancers most frequently associated
with VTE complications. In one study, it was identified as
the second most frequent VTE-related cancer (OR= 2.37,
95% CI, 2.04–274) (28). Furthermore, neurological surgery
has been shown to be associated with VTE (29), which was
confirmed in our study.
Hemorrhagic stroke is considered to be highly associated
with DVT and PE (3,4), but this was not the case in our
study. In fact, we found a negative association with fatal PE
in stroke patients, which may be explained by the severity of
their conditions. In 48 of the 53 patients in the control group
(90.6%), the hemorrhage itself was the main cause of death.
These patients also had short hospital stays prior to their
deaths, which may have prevented the development of VTE.
After excluding 1 patient who was in the hospital for 122
days, the average hospital stay of these patients was 8.48
days.
Aortic aneurism and cirrhosis were also found to have a
negative association with fatal PE. Only 1 patient in the fatal
PE group had an aortic aneurism, and his hospital stay was
99 days. Of the 19 patients in the control group, 13 (68.4%)
died from the dissection or rupture of the aneurism, and 10
died prior to the third day of admission. Of the cirrhotic
patients in the control group, 29 (50%) died from bleeding
complications, and the median hospital stay prior to death
for these patients was only 7 days.
One interesting finding of our study was the strong
association between atherosclerosis and fatal PE
(OR= 4.03, 95% CI, 1.06–15.71, p= 0.040). Although athero-
sclerosis is not typically thought to be an independent risk
factor for VTE (30,31), intriguing evidence from recent
studies has suggested that statins may prevent VTE in
healthy older adults (32,33). In a randomized, double-
blind, placebo-controlled trial, 20 mg of rosuvastatin daily
significantly reduced the occurrence of symptomatic VTE
in outpatients with no cardiovascular disease histories.
The PE rates were 0.09 in the rosuvastatin group and 0.12
in the placebo group (HR= 0.77, 95% CI, 0.41–1.45, p= 0.42)
(32). The anti-inflammatory effect of statins on the
microvascular endothelium may be the possible mechan-
ism of action (33). Another interesting finding was the
negative association between pneumonia and fatal PE.
Pneumonia has classically been considered a risk factor for
VTE (3,4), and it is unclear why our data did not confirm
this association.
AIDS is considered to present many risk factors for VTE,
including frequent hospitalization, the use of central venous
catheters, an age older than 45 years, and the activation of
endothelial cells from infections with cytomegalovirus,
herpes, and HIV itself (34,35). The mean age of the AIDS
patients in our study was 43.7 years, and the average
hospital stay of these patients was only 11.1 days. These
findings may indicate that these patients presented to the
hospital with serious conditions that did not allow enough
time for PE to develop.
Table 3 - Age and length of hospital stay according to reason for admission.
Reason for admission Mean age Mean length of stay
Fatal PE, Years (n) Non-PE, Years (n) p Fatal PE, Days (n) Non-PE, Days (n) p-value
AIDS 43.7 (7) 42.2 (38) 0.40 16.4 (7) 11.1 (38) 0.080
AMI 61.9 (15) 66.0 (31) 0.15 5.7 (15) 7.6 (31) 0.24
Aortic aneurism 65.0 (1) 66.1 (19) – 99.0 (1) 8.8 (19) –
Arterial insufficiency 74.1 (17) 75.1 (15) 0.40 8.5 (17) 13.9 (15) 0.070
Cancer 60.6 (135) 61.5 (196) 0.30 12.5 (135) 12.1 (196) 0.40
CHF 66.2 (37) 71.3 (39) 0.06 5.8 (37) 5.8 (39) 0.49
Chronic renal failure 59.2 (6) 53.5 (10) 0.29 18.7 (6) 6.2 (10) 0.020
Cirrhosis 56.3 (3) 56.6 (58) 0.49 3.0 (3) 15.7 (58) 0.060
COPD 69.3 (16) 68.9 (13) 0.47 5.6 (16) 10.5 (13) 0.060
Infection 66.5 (26) 65.9 (84) 0.43 13.9 (26) 15.8 (84) 0.34
Mesenteric ischemia 64.0 (3) 60.8 (12) 0.36 5.7 (3) 7.0 (12) 0.43
Rheumatologic disease 40.5 (6) 40.2 (13) 0.47 13.2 (6) 13.1 (13) 0.49
Stroke, hemorrhagic 54.7 (6) 62.2 (53) 0.15 13.5 (6) 10.6 (53) 0.36
Stroke, ischemic 69.6 (14) 64.6 (25) 0.16 9.0 (14) 8.4 (25) 0.43
PE: pulmonary embolism; AIDS: acquired immunodeficiency syndrome; AMI: acute myocardial infarction; CHF: congestive heart failure and COPD: chronic
obstructive pulmonary disease.
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Table 4 - Conditional univariate logistic regression of association between risk factors and fatal PE adjusted for sex, age
and time of admission.
Factor Variable Cases n Controls n Standard Error OR 95% CI p-value
AIDS 7 38 0.14 0.30 0.12–0.77 0.010
AMI 15 31 0.33 0.99 0.52–1.91 0.99
Aortic aneurism 1 19 0.12 0.11 0.14–0.88 0.040
Arterial insufficiency 17 15 0.72 1.93 0.93–4.00 0.080
Atherosclerosis 7 3 3.15 4.65 1.23–17.52 0.020
Cancer 135 196 0.26 1.72 1.28–2.32 ,0.001
Biliary tract 6 11 0.60 1.11 0.38–3.21 0.85
Bladder 2 3 1.80 1.80 0.26–12.4 0.55
Brain 15 10 1.25 2.91 1.25–6.74 0.010
Breast 9 8 1.44 2.71 0.95–7.70 0.060
Colorectal 12 16 0.63 1.32 0.52–3.34 0.56
Esophagus 4 9 0.45 0.70 0.20–2.47 0.57
Head and neck 4 13 0.40 0.68 0.21–2.17 0.51
Kidney 2 3 1.68 1.59 0.20–12.5 0.66
Leukemia 5 15 0.40 0.73 0.25–2.13 0.56
Liver 3 2 0.38 0.56 0.15–2.11 0.39
Lung 12 26 0.34 0.88 0.42–1.86 0.75
Lymphoma 10 20 0.43 1.04 0.47–2.34 0.92
Melanoma 2 2 1.58 1.53 0.20–11.55 0.68
Myeloma 3 2 4.02 3.99 0.55–28.80 0.170
Ovarian 3 4 1.17 1.52 0.34–6.84 0.59
Pancreas 9 9 1.08 2.18 0.83–5.73 0.120
Prostate 6 6 1.18 1.98 0.62–6.38 0.25
Stomach 8 10 0.68 1.35 0.50–3.64 0.56
Undetermined 8 4 2.44 3.94 1.17–13.28 0.030
Uterus 10 9 1.16 2.42 0.95–6.21 0.070
CHF 37 39 0.54 2.14 1.30–3.50 0.003
Cirrhosis 3 58 0.06 0.10 0.03–0.33 ,0.001
COPD 16 13 1.12 2.75 1.24–6.10 0.010
Chronic renal failure 6 10 0.63 1.22 0.44–3.36 0.70
Infection 26 84 0.14 0.60 0.38–0.97 0.040
Endocarditis 3 8 0.27 0.25 0.30–2.08 0.200
Peritonitis 1 8 0.46 0.57 0.12–2.82 0.49
Pneumonia 8 39 0.16 0.39 0.18–0.85 0.020
Tuberculosis 6 11 0.68 1.29 0.46–3.62 0.63
Urinary 5 3 2.21 3.01 0.71–12.74 0.140
Mesenteric ischemia 3 12 0.29 0.43 0.11–1.61 0.21
Surgery 57 98 0.22 1.17 0.80–1.69 0.42
Abdominal 15 36 0.24 0.75 0.40–1.42 0.38
Neurological 14 33 0.68 1.78 0.84–3.78 0.130
Thoracic 5 5 1.37 2.13 0.60–7.52 0.24
Vascular 12 24 0.33 0.84 0.39–1.81 0.65
Rheumatologic diseases 6 13 0.44 0.89 0.34–2.37 0.82
Stroke 20 78 0.12 0.44 0.26–0.74 0.002
Hemorrhagic 6 53 0.08 0.19 0.08–0.47 ,0.001
Ischemic 14 25 0.33 0.91 0.44–1.84 0.79
VTE Prophylaxis 134 454 0.18 0.70 0.42–1.16 0.170
OR: odds ratio; CI: confidence interval; AIDS: acquired immunodeficiency syndrome; AMI: acute myocardial infarction; CHF: congestive heart failure and
COPD: chronic obstructive pulmonary disease.
Table 5 - Conditional multivariate logistic regression of the association between risk factors and fatal PE, adjusted for
age and time of admission.
Factor Variable Cases n Controls n Standard Error OR 95% CI p-value
AIDS 7 38 0.11 0.22 0.08–0.60 0.003
Aortic aneurism 1 19 0.12 0.12 0.01–0.90 0.040
Atherosclerosis 7 3 2,80 4.03 1.06–15.71 0.040
CHF 37 39 0.47 1.77 1.04–2.97 0.030
Cirrhosis 3 58 0.05 0.08 0.03–0.27 ,0.001
Pneumonia 8 39 0.15 0.35 0.15–0.79 0.010
Neurological surgery 14 33 2.00 3.96 1.48–10.65 0.006
Stroke, hemorrhagic 6 53 0.05 0.09 0.03–0.25 ,0.001
OR: odds ratio; CI: confidence interval; AIDS: acquired immunodeficiency syndrome and CHF: congestive heart failure.
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One recent publication that evaluated the adequacy of
VTE prophylaxis in 37,356 hospitalized patients across 32
countries reported that thromboprophylaxis was prescribed
for only 50% of these patients (18,19). In our hospital, the
use of VTE prophylaxis has only increased during recent
years, which suggests that we would expect to observe low
rates of prophylaxis during the period studied. This finding
proved accurate, as only 20.4% of patients in this study
received adequate prophylaxis. This low prophylaxis rate
may explain why no association between prophylaxis and
fatal PE was found.
This study evaluated a large number of autopsies
performed on hospital patients who had been admitted for
general medical care or surgery; atherosclerosis, CHF, and
neurological surgery were found to be associated with fatal
PE. AIDS, aortic aneurism, cirrhosis, and hemorrhagic
stroke were negatively associated with fatal PE, and this
finding may be explained by the severity of these condi-
tions, which often led to patient death after a short hospital
stay and before PE could develop.
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